Precigen

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Precigen (PGEN) reports strong Q1 performance and growth opportunities

Precigen's Q1 2023 earnings call highlighted financial strength, progress in innovative therapies, and a focus on cost-effective drug development.
The company's platforms like PRGM 2012 and UltraCAR show promise in treating challenging diseases, supported by a solid cash runway into late 2024.
While facing challenges in program transparency and target rights, Precigen's opportunities lie in rapid commercialization, personalized medicine, and market expansion.

Precigen (PGEN) reports strong Q2 performance and FDA alignment

Precigen (PGEN) shows promising performance with positive Phase I data for PRGN-2012 and cost-saving measures implemented.
Strengths lie in FDA confirmation, positive regulatory developments, and extended cash runway to 2025.
Challenges include safety follow-up, commercial readiness, and balancing program focus amidst cost-saving measures.
Opportunities arise from international licensure discussions, repeat dosing scenarios, and FDA alignment for accelerated approval.

Precigen (PGEN) projects strong growth in 2024 with key milestones

Precigen (PGEN) anticipates a significant year ahead with key milestones for PRGN-2012 and UltraCAR-T therapies.
Financially, the company aims to balance R&D investments with cost reductions to support strategic initiatives.
Analysts' inquiries and the focus on strengthening the balance sheet underscore the company's commitment to sustainable growth.

Precigen (PGEN) excels with PRGN-2012 gene therapy, poised for growth

Precigen (PGEN) showcased strong performance with PRGN-2012, supported by positive clinical trial outcomes and regulatory milestones.
While challenges like trial enrollment pace and market strategies exist, strategic initiatives and financial updates indicate a proactive approach to addressing them.
The company's focus on commercialization and workforce optimization presents opportunities for growth and market leadership in the gene therapy sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

– Fast Track designation received for PRGN-3006 UltraCAR-T®, an important milestone for patients with relapsed or refractory acute myeloid leukemia, a rapidly progressing disease with limited treatment option s –  – Phase 1b expansion arm initiated for PRGN-3006 UltraCAR-T ® at Dose Level 3 with lymphodepletion   – –  Dosing initiated in patients at Dose Level 3 via intravenous infusion with lymphodepletion in the PRGN-3005 UltraCAR-T® Phase 1 study – –  Phase 2 study initiated for PRGN-2012 AdenoVerse ™ Immunotherapy as an adjuvant treatment in patients with recurrent respiratory papillomatosis – – Cash, cash equivalents, short-term and long-term investments totaled $142.1 million as of March 31, 2022 – – Company to host a pipeline update call in the coming months  – GERMANTOWN, Md. , May 9, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced first quarter 2022 financial results and business updates.

Precigen Reports First Quarter 2022 Financial Results and Business Updates

Precigen, Inc. (PGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Precigen, Inc. (PGEN) Expected to Beat Earnings Estimates: Should You Buy?

Precigen (PGEN) is developing CAR T therapy candidate, PRGN-3006 UltraCAR-T, for treating acute myeloid leukemia in a phase I study. The FDA grants Fast Track designation.

Precigen (PGEN) Up on FDA Fast Track Tag for CAR-T Candidate

–   Acute myeloid leukemia (AML) is among the most common types of leukemia in adults – –   PRGN-3006 UltraCAR-T previously  received orphan drug designation (ODD) in patients with AML by the US Food and Drug Administration (FDA) – –   PRGN-3006 UltraCAR-T has demonstrated a favorable safety profile to date with no dose-limiting toxicities or neurotoxicity, and has demonstrated dose-dependent in vivo expansion and durable persistence – GERMANTOWN, Md. , April 4, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the FDA has granted Fast Track designation for PRGN-3006 UltraCAR-T® in patients with relapsed or refractory (r/r) AML (clinical trial identifier: NCT03927261).

Precigen Receives Fast Track Designation for PRGN-3006 UltraCAR-T® in Patients with Relapsed or Refractory Acute Myeloid Leukemia

NEW YORK--(BUSINESS WIRE)-- #Class--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Precigen, Inc. f/k/a Intrexon Corporation (NASDAQ: PGEN; XON) on behalf of long-term stockholders following a class action complaint that was filed against Precigen on October 5, 2020 with a Class Period from May 10, 2017 to September 25, 2020. Our investigation concerns whether the board of directors of Precigen have breached their fiduciary

PRECIGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Precigen, Inc. f/k/a Intrexon Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 7.14% and 14.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Precigen, Inc. (PGEN) Reports Q4 Loss, Tops Revenue Estimates

GERMANTOWN, Md., March 1, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced fourth quarter and full year 2021 financial results.

Precigen Reports Fourth Quarter and Full Year 2021 Financial Results

GERMANTOWN, Md., Jan. 12, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today presented pipeline and corporate updates at the 40th Annual J.P.

Precigen Provides Pipeline and Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference

Precigen, Inc. (PGEN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why Precigen, Inc. (PGEN) Could be Great Choice for a Bottom Fisher

Precigen has highly differentiated platforms in the field of Gene and Cell Therapy.

Precigen: A Substantially Undervalued And Differentiated Gene Therapy Company

GERMANTOWN, Md. , Jan. 5, 2022 /PRNewswire/ --  Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will present a corporate and clinical overview at the 40th Annual J.P.

Precigen to Present at the 40th Annual J.P. Morgan Healthcare Conference

Codexis

Verve Therapeutics

Here we discuss three stocks - CDXS, PGEN, VERV - engaged in the field of scientific biology that investors may keep a tab of as these have the potential to generate wealth for them going forward.

3 Synthetic Biology Stocks in Focus With Strong Potential

Precigen Inc (NASDAQ: PGEN) presented positive interim data at the ASH Annual Meeting and Exposition from the ongoing Phase 1/1b study of PRGN-3006 UltraCAR-T in relapsed or refractory (r/r) acute myeloid leukemia and higher-risk myelodysplastic syndromes. PRGN-3006 UltraCAR-T is a multigenic autologous CAR-T simultaneously expressing a CAR targeting CD33.

Precigen Reveals Early Data From CAR-T Candidate In Blood Cancer Patients

GERMANTOWN, Md., Dec. 13, 2021 /PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today presented positive interim data at the 63rd ASH Annual Meeting and Exposition (Abstract# 825) from the ongoing Phase 1/1b clinical study of PRGN-3006 UltraCAR-T® in patients with relapsed or refractory (r/r) acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (MDS) (clinical trial identifier: NCT03927261).

Precigen Announces Positive Interim Phase 1 Data for PRGN-3006 UltraCAR-T® in Relapsed or Refractory Acute Myeloid Leukemia

Investors need to pay close attention to Precigen (PGEN) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Precigen (PGEN) Stock?

GERMANTOWN, Md., Nov. 10, 2021 /PRNewswire/ --  Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will participate in the Stifel 2021 Virtual Healthcare Conference on Wednesday, November 17, 2021 at 10:40 AM ET.

Precigen to Present at the Stifel 2021 Virtual Healthcare Conference

GERMANTOWN, Md., Nov. 4, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, announced a topline summary of the presentations planned for today's 2021 R&D Day virtual event, which begins at 11:00 AM ET.

Precigen Achieves Significant Clinical Progress for UltraCAR-T® and AdenoVerse™ Therapies

GERMANTOWN, Md., Oct. 27, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company will host a virtual event on Thursday, November 4, 2021 at 11:00 AM ET to provide an update on the progress for its clinical pipeline.

Precigen to Host R&D Update Virtual Event on November 4th to Share Clinical Developments

GERMANTOWN, Md., Oct. 26, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application to initiate the Phase 1/1b clinical trial of PRGN-3007 in advanced receptor tyrosine kinase-like orphan receptor 1-positive (ROR1+) hematological and solid tumors.

Precigen Announces Clearance of IND to Initiate Phase 1/1b Study for PRGN-3007 UltraCAR-T® in Advanced ROR1+ Hematological and Solid Tumors

GERMANTOWN, Md., Oct. 12, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the appointment of Harry Thomasian Jr. as the Company's chief financial officer (CFO), effective October 18, 2021.

Precigen Appoints Harry Thomasian Jr. as Chief Financial Officer

Implied Volatility Surging for Precigen (PGEN) Stock Options

Precigen Inc's (NASDAQ: PGEN) subsidiary Precigen ActoBio has announced additional interim data from Phase 1b/2a study of AG019 ActoBiotics for recent-onset type 1 diabetes (T1D). Related:   Precigen Stock Surges On Positive AG019 Data for Chronic Treatment Of Type 1 Diabetes.

Precigen Posts Additional Interim Data From Type 1 Diabetes Trial

GERMANTOWN, Md., Oct. 1, 2021 /PRNewswire/ -- Precigen ActoBio, an innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents and a wholly-owned subsidiary of Precigen, Inc. (Nasdaq: PGEN), today announced additional positive interim data from the ongoing Phase 1b/2a clinical study investigating AG019 ActoBiotics™ for the treatment of recent-onset type 1 diabetes (T1D) (clinical trial identifier: NCT03751007, EudraCT 2017-002871-24).

Precigen ActoBio Announces Additional Positive Interim Data from Phase 1b/2a Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes

GERMANTOWN, Md., Sept. 1, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in two upcoming conferences.

Precigen to Present at the 2021 Wells Fargo Virtual Healthcare Conference and the H.C. Wainwright 23rd Annual Global Investment Conference

Precigen, Inc. (PGEN) CEO Helen Sabzevari on Q2 2021 Results - Earnings Call Transcript

News for Precigen Stock (PGEN)